Arch Biopartners Dirección

Dirección controles de criterios 3/4

El CEO de Arch Biopartners' es Richard Muruve , nombrado en Aug 2009, tiene una permanencia de 14.75 años. compensación anual total es CA$150.00K, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 15% de las acciones de la empresa, por valor de CA$16.61M. La antigüedad media del equipo directivo y de la junta directiva es de 12.7 años y 14 años, respectivamente.

Información clave

Richard Muruve

Chief Executive Officer (CEO)

CA$150.0k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	14.8yrs
Participación del CEO	15.0%
Permanencia media de la dirección	12.7yrs
Promedio de permanencia en la Junta Directiva	14yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Richard Muruve en comparación con los beneficios de Arch Biopartners?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CA$2m
Sep 30 2023	CA$150k	CA$150k	-CA$3m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$4m
Dec 31 2022	n/a	n/a	-CA$3m
Sep 30 2022	CA$113k	CA$113k	-CA$1m
Jun 30 2022	n/a	n/a	-CA$257k
Mar 31 2022	n/a	n/a	-CA$423k
Dec 31 2021	n/a	n/a	CA$308k
Sep 30 2021	CA$100k	CA$100k	-CA$1m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$383k	CA$100k	-CA$5m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	n/a	n/a	-CA$2m
Sep 30 2019	CA$100k	CA$100k	-CA$2m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	n/a	n/a	-CA$3m
Sep 30 2018	CA$100k	CA$100k	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$2m
Dec 31 2017	n/a	n/a	-CA$2m
Sep 30 2017	CA$100k	CA$100k	-CA$2m

Compensación vs. Mercado: La compensación total de Richard($USD109.83K) está por debajo de la media de empresas de tamaño similar en el mercado Canadian ($USD175.44K).

Compensación vs. Ingresos: La compensación de Richard ha aumentado mientras la empresa no es rentable.

CEO

Richard Muruve (52 yo)

14.8yrs

Permanencia

CA$150,000

Compensación

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and President since May 12, 2010. Mr. Muruve served as Acting Chief Financial...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Muruve	Co-Founder	14.8yrs	CA$150.00k	15% CA$ 16.1m
Daniel Muruve	Co-Founder	12.7yrs	CA$289.00k	2.92% CA$ 3.1m
Andrew Bishop	CFO & Director	no data	CA$289.00k	0.76% CA$ 819.3k
Justin MacDonald	Co-Founder & Principal Scientist	no data	sin datos	sin datos
Paul Beck	Co-Founder & Principal Scientist	no data	sin datos	sin datos
Aaron Benson	Director of Communications	less than a year	sin datos	sin datos

12.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ARCH es experimentado (12.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Muruve	Co-Founder	18.8yrs	CA$150.00k	15% CA$ 16.1m
Daniel Muruve	Co-Founder	no data	CA$289.00k	2.92% CA$ 3.1m
Andrew Bishop	CFO & Director	14.1yrs	CA$289.00k	0.76% CA$ 819.3k
Claude Allary	Independent Director	10.1yrs	CA$289.00k	0.33% CA$ 353.3k
Richard Rossman	Independent Director	14yrs	sin datos	3.4% CA$ 3.7m
Robert Hodges	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hindrik Mulder	Member of Scientific Advisory Board	no data	sin datos	sin datos

14.0yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de ARCH son experimentados ( 14 años antigüedad media).

Arch Biopartners Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Recent updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.035 loss in 1Q 2023)

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.008 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.003 loss in 1Q 2022)

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Third quarter 2021 earnings released: EPS CA$0.014 (vs CA$0.037 loss in 3Q 2020)

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

New 90-day low: CA$1.25

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

New 90-day low: CA$1.26

Full year 2020 earnings released: CA$0.077 loss per share (vs CA$0.036 loss in FY 2019)

New 90-day low: CA$1.37

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

New 90-day high: CA$1.56

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

New 90-day low - CA$1.24

Third quarter earnings released

New 90-day low - CA$1.25

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad